H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nuvation Bio (NUVB – Research Report) today and set a price target of $4.50. The company’s shares closed last Friday at $2.09.
According to TipRanks, Burns is an analyst with an average return of -22.7% and a 22.60% success rate. Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE.
Nuvation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.45 and a one-year low of $1.92. Currently, Nuvation Bio has an average volume of 616.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
